Background: Recent studies have indicated that depression is associated with persistent postoperative pain and decreased satisfaction following foot and ankle surgery. This study aimed to evaluate the effect of perioperative duloxetine on postoperative outcomes of anterior talofibular ligament (ATFL) surgical repair for chronic ankle instability (CAI) in patients with depression. We further sought to evaluate patients' satisfaction and side effects related to duloxetine.

Material And Methods: Patients undergoing ATFL repair were screened for depression preoperatively with the Patient Health Questionnaire (PHQ-9). Among 249 patients who underwent arthroscopic or open surgical Brostrom repair of the ATFL, 120 patients were identified as being "possibly depressed" and were included in the study. Sixty patients were randomly assigned to the duloxetine group (one day preoperatively and for 6 weeks postoperatively), and the other sixty were randomized to the placebo group. Painkillers and opioid consumption, pain scores, and patient satisfaction were recorded at 12, 24, 48, and 72hours postoperatively and at follow-up visits 1, 3, and 6 months after surgery. Patient-reported outcome measures (PROMs) were assessed preoperatively and at 3, 6, 12 and 24 months postoperatively. Duloxetine-related side effects such as nausea/vomiting and fatigue were also recorded.

Results: The patients in the duloxetine group reported a significantly longer time to rescue analgesic and reduced opioid requirements (including celecoxib, pregabalin, acetaminophen, and tramadol). The patients experienced decreased pain intensity and greater satisfaction with their pain management at 24, 48, 72h and 1 and 3 months after surgery (p<0.05). The duloxetine group also had significantly better clinical and functional outcomes at 3 and 6 months of follow-up compared to the placebo group (p<0.05). The occurrence and rate of symptoms of duloxetine side effects were not significant.

Discussion: Depression is an important factor to consider and address because its presence before surgery can predict poor postoperative outcomes, including more severe postoperative pain, persistent postoperative pain, and increased consumption of painkillers and opioids.

Conclusion: Perioperative administration of duloxetine following ATFL repair for CAI in patients with depression increased the time to first postoperative rescue analgesic request and reduced both opioid consumption and postoperative pain. This approach also led to a high level of patient satisfaction. In addition, duloxetine improved the quality of recovery without leading to significant side effects.

Level Of Evidence: I; prospective randomized controlled trial.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.otsr.2024.103837DOI Listing

Publication Analysis

Top Keywords

perioperative duloxetine
8
postoperative outcomes
8
outcomes anterior
8
anterior talofibular
8
talofibular ligament
8
repair chronic
8
ankle instability
8
patients
8
patients depression
8
side effects
8

Similar Publications

Pain Management in Brugada Syndrome: A Case Report and Review.

A A Pract

January 2025

Division of Anaesthesiology and Perioperative Medicine, Department of Pain Medicine, Singapore General Hospital, Singapore.

Article Synopsis
  • Brugada syndrome is a rare condition that elevates the risk of serious heart arrhythmias, with limited guidance on pain management for these patients.
  • A case study of a young woman with the syndrome highlights the use of ropivacaine peripheral nerve infusion and intravenous ketamine for managing her acute-on-chronic pain in the left upper limb.
  • The approach included a multimodal analgesia strategy with neuropathic agents and opioids, aiming to improve safe pain management practices for those with Brugada syndrome.
View Article and Find Full Text PDF

Perioperative Duloxetine in Total Joint Arthroplasty: An Umbrella Review.

J Perianesth Nurs

November 2024

Department of Orthopedics, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, China. Electronic address:

Purpose: Duloxetine, a serotonin and norepinephrine reuptake inhibitor primarily used for chronic neuropathic pain, has been debated for its efficacy in total joint arthroplasty contexts.

Design: Umbrella review.

Methods: A comprehensive search spanning PubMed, CINAHL, OVID, Embase, MEDLINE, CENTRAL, Google Scholar, and Cochrane, with no language restrictions up to January 2024, was conducted.

View Article and Find Full Text PDF

Background: High pain levels immediately after surgery have been associated with persistent postsurgical pain. Still, it is uncertain if analgesic treatment of immediate postsurgical pain prevents the development of persistent postsurgical pain.

Methods: We searched MEDLINE, CENTRAL, and Embase up to September 12, 2023, for randomized controlled trials investigating perioperative analgesic interventions and with reported pain levels 3 to 24 months after total hip or knee arthroplasty in patients with osteoarthritis.

View Article and Find Full Text PDF

Purpose: Little is known about the optimal analgesia regimen after HTO. Thus, this study systematically reviewed the literature on clinical and patient-reported outcomes of pain management strategies for patients after HTO.

Methods: A comprehensive search of the PubMed, Cochrane CENTRAL, and CINAHL databases was conducted from inception through September 2023.

View Article and Find Full Text PDF

Background: The opioid crisis has become a present concern in the medical field. In an effort to address these complications, antineuropathic pain medications have been considered as alternatives to prescribed opioids.

Objective: This review focuses on the analgesic effects of neuromodulators, such as gabapentin, duloxetine, and pregabalin, that provide room for less dependence on narcotic analgesics following orthopedic surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!